The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex Therapeutics’ experimental immunotherapy Allocetra for primary, age-related knee osteoarthritis in patients aged 64 and older.
RMAT designation is intended to give the company more frequent and earlier engagement with the FDA while Allocetra advances through clinical development. The status can also make the therapy eligible for accelerated approval and priority review, potentially shortening the regulatory path if subsequent data support such actions.
Enlivex said the designation reflects confidence in results from its completed Phase I/IIa trial. In that study, patients with primary age-related knee osteoarthritis who received Allocetra experienced statistically significant improvements in pain and physical function compared with placebo. Those benefits were reported to persist for at least six months.
The company has moved forward with a randomized, controlled Phase IIb trial conducted across the United States and Europe. The study aims to enroll 182 patients aged 64 and older with primary knee osteoarthritis. Enlivex reported that the first U.S. patient in the Phase IIb study has been dosed, and it expects to report top-line data by the end of the second quarter of 2027.
In addition to granting RMAT status, the FDA has requested a Type B meeting with Enlivex to discuss the broader Allocetra development program. The agency intends to review elements of the Phase IIb design and planning for a potential pivotal trial; Enlivex said it plans to schedule the Type B meeting in the coming months.
More broadly, the company framed the RMAT decision as a potential way to expedite development of a treatment for a condition that affects a large and growing aging population and for which current therapeutic options are limited. The article notes that more than 32 million Americans currently live with knee osteoarthritis, a population projected to increase to roughly 78 million by 2040. Severe cases often require total knee replacement.
The designation and upcoming regulatory interactions come as Enlivex advances a mid-stage program with defined enrollment and an expected data timeline. The company’s next steps include continuing enrollment in the Phase IIb trial, conducting the FDA Type B meeting to align on development plans, and pursuing the top-line results targeted for late Q2 2027.
Investors and healthcare market participants will monitor the trial’s progress, regulatory engagement, and the company’s ability to meet its enrollment and data-readout timelines.